



Docket No.: 50229-267

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Peter Anthony CROOKS, et al.

Serial No.: 09/881,215

Group Art Unit: 1646

Filed: June 15, 2001

Examiner:

For: AGMATINE AND AGMATINE ANALOGS IN THE TREATMENT OF EPILEPSY,  
SEIZURE AND ELECTROCONVULSIVE DISORDERS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Each English language reference was cited in a corresponding application search report or office action and its relevance discussed therein. A copy of the search report or office action is attached for the Examiner's information.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

*Robert L. Price*  
*Daniel Bucca 42368 for*

Robert L. Price  
Registration No. 22,685

600 13<sup>th</sup> Street, N.W.  
Washington, DC 20005-3096  
(202) 756-8000 RLP:prp  
**Date: December 27, 2001**  
Facsimile: (202) 756-8087